



STATE OF WEST VIRGINIA
DEPARTMENT OF HUMAN SERVICES
BUREAU FOR MEDICAL SERVICES

Alex J. Mayer, PhD, MS, PMP
Cabinet Secretary

Cynthia Beane, MSW, LCSW
Commissioner

**West Virginia Medicaid Drug Utilization Review Board Minutes
11.19.2025**

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Scott Brown, RPh
Phillip Galapon, MD
Lester Labus, MD
Mary Nemeth-Pyles, MSN, RN, CS
Kate Forman, PharmD
C.K. Babcock, PharmD
Chris Booth, PharmD
Michael Lonsinger, PharmD

Members Absent:

Christopher Terpening, PharmD, PhD, Chair
David Gloss, MD, Vice Chair
Michael Ballow, PharmD
Ernest Miller, DO

Department of Human Services (DoHS)/Bureau for Medical Services (BMS) Staff:

Vicki Cunningham, PharmD, Director of Pharmacy
Gail Goodnight, PharmD
Lori Moles, PharmD
Doug Sorvig, Data Analyst
William Hopkins, PharmD, Pharmacy Operations Manager
Kristen Boustany, PharmD
Kevin McCann, WV Medicaid Medical Director

Other Contract/State Staff Present:

Priya Shah, PharmD, Drug Utilization Review Coordinator
Joe Bergondo, PharmD – Change Healthcare
Roberta Capp, MD – Optum Rx
Eric Sears, RPh -- Gainwell
Angie Wowczuk, PharmD – Rational Drug Therapy Program (RDTP)
Cory Chambliss – Acentra Health
Scott Donald, PharmD – Acentra Health
Rachele Poissant, PharmD – Acentra Health

1. INTRODUCTIONS

- a. Dr. Philip Galapon, Chair, welcomed everyone to the Board meeting at 4:05 PM (EST). The DUR Board and others introduced themselves.



2. APPROVAL OF MINUTES FROM May 21, 2025 and September 24, 2025 DUR BOARD MEETING

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting with no further discussion

3. OLD BUSINESS

- a. None

4. NEW BUSINESS

a. Speakers

- i. None

b. Updates from October 22, 2025 Pharmaceutical & Therapeutics (P&T) Committee Meeting

- i. Dr. Joe Bergondo presented the PDL status updates from the October 22, 2025, P&T meeting.

c. Prior Authorization Criteria. Attachment A.

- i. **Wegovy**-approved as written
- ii. **Qelbree**- approved as written
- iii. **Paxlovid**- approved as written
- iv. **Ebglyss**- approved as written
 - i. Approval to update statement in other four therapies as well
- v. **Ubrelyvy**- approved as written
- vi. **Kesimpta**- approved as proposed
- vii. **Airsupra**- approved as written
- viii. **Hepatitis C**- removal of prior authorization – approved as proposed
- ix. **Vraylar**- approved as written
- x. **Agamree**- approved as written
- xi. **Non-Factor Replacement**: Alhemo, Hymravzi, Qfitlia – approved as written

5. REPORTS—3rd QUARTER 2025

- a. **Gainwell Technologies Quarterly Report:** Mr. Eric Sears presented an overview of the 2025 third quarter report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Angela Wowczuk presented a summary of the prior authorization program for the third quarter of 2025. Attachment C.
- c. **Acentra Health:** Dr. Rachele Poissant presented a summary of the RDUR interventions for the third quarter of 2025. Attachment D.

6. OTHER BUSINESS

- a. None

7. NEXT MEETING AND ADJOURNMENT

- a. The meeting concluded at 5:35 PM (EST). The next meeting will be February 2026, date TBD.

